FONDAPARINUX USAGE IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME
https://doi.org/10.15829/1560-4071-2015-9-88-91
Abstract
Anticoagulation treatment is a vital component of acute coronary syndrome treatment. Selection of the most efficient and safe drug for the acute coronary syndrome patients without ST elevation (NSTEACS) depends on the strategy of treatment and is in fact a difficult task. Fondaparinux (Arixtra) is a synthetic Xa factor clotting inhibitor, has showed its benefits in clinical studies, according to which it is included into clinical guidelines. Current review focuses on the main results and conclusions of the studies, and the place for fondaparinux in clinical practice is described
About the Authors
G. V. Mardaryan
Russian Scientific Center of Surgery named after B. V. Petrovsky, Moscow
Russian Federation
Russian Federation
S. A. Abugov
Russian Scientific Center of Surgery named after B. V. Petrovsky, Moscow;
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
Russian Federation
References
1. Wijns W, Kolh P, Danchin N, et al. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 2014; 35: 2541-619.
2. Karthikeyan G, Mehta SR, Eikelboom JW. Fondaparinux in the Treatment of Acute Coronary Syndromes: Evidence from OASIS 5 and 6. Expert Rev Cardiovasc Ther. 2009; 7(3): 241-9.
3. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. European Heart Journal. 2007; 28(17): 2077-86.
4. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114(8): 774-82.
5. Инструкция к препарату Арикстра. http://grls.rosminzdrav.ru/Grls_View_ v2.aspx?idReg=287716&t=
6. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. Journal of American College of Cardiology. 2007; 50 (18):1742-51.
7. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 2006; 354(14): 1464-76.
8. Szummer K, Oldgren J, Lindhagen L, et al. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. JAMA 2015; 313: 707-16.
9. Hirsh J, O’Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116(5): 552-60.
10. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N. Engl. J. Med. 2006; 355(10): 1006-17.
11. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non– ST–Ele vation Myocardial Infarction. J Am Coll Cardiol, 2007; 50:652–726, doi:10.1016/j. jacc.2007.02.028 (Published online 6 August 2007).
Review
For citations:
Mardaryan G.V., Abugov S.A. FONDAPARINUX USAGE IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME. Russian Journal of Cardiology. 2015;(9):88-91. (In Russ.) https://doi.org/10.15829/1560-4071-2015-9-88-91
Views:
828
Email this article 